SCHEMBL1450262

SCHEMBL1450262

O=c1[nH]c2ccccc2c2sccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.57
KDM4E B2RXH2 7/20 0.57
TNKS O95271 3/20 0.57
TNKS2 Q9H2K2 3/20 0.57
ALDH1A1 P00352 3/20 0.57
PARP15 Q460N3 2/20 0.57
LMNA P02545 2/20 0.57
MEN1 O00255 1/20 0.57
CYP1A2 P05177 1/20 0.57
GPR3 P46089 1/20 0.57
BLM P54132 1/20 0.57
PMP22 Q01453 1/20 0.57
KMT2A Q03164 1/20 0.57
HSD17B10 Q99714 1/20 0.57
CSNK2A1 P68400 2/20 0.56
CSNK2A2 P19784 1/20 0.56
CSNK2B P67870 1/20 0.56
CDK4 P11802 1/20 0.51
CCND1 P24385 1/20 0.51
CA12 O43570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30273090 1.00 PARP1 (0.57) PARP1KDM4ETNKSTNKS2ALDH1A1
SCHEMBL5879688 0.89 PARP1 (0.53) PARP1KDM4ETNKSTNKS2ALDH1A1
SCHEMBL2546622 0.85 KDM4E (0.59) PARP1KDM4ETNKSTNKS2ALDH1A1
SCHEMBL30273107 0.85 KDM4E (0.59) PARP1KDM4ETNKSTNKS2ALDH1A1
Hydrochloric Acid SCHEMBL2571835 0.84 KDM4E (0.58) PARP1KDM4ETNKSTNKS2ALDH1A1
Hydrochloric Acid SCHEMBL16858767 0.84 KDM4E (0.58) PARP1KDM4ETNKSTNKS2ALDH1A1
SCHEMBL7343430 0.82 KDM4E (0.57) PARP1KDM4ETNKSTNKS2ALDH1A1
SCHEMBL20631258 0.81 PARP1 (0.64) PARP1KDM4ETNKSTNKS2ALDH1A1
SCHEMBL17109319 0.79 PARP1 (0.55) PARP1KDM4ETNKSTNKS2ALDH1A1
SCHEMBL13558618 0.79 PARP1 (0.53) PARP1KDM4ETNKSTNKS2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210220408-A1 ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE EDIGENE BIOTECHNOLOGY, INC. (CN) 2021-07-22 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
CN-101528704-B Serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS INC 2014-04-09 CN disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
WO-2009097014-A2 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-08-06 WO disclosed
EP-2061765-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS Cylene Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210220408-A1 ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE AHR, ARNT, ARSA PARP1 3109/4885KDM4E 1784/4885TNKS 3453/4885
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS PACSIN2, CKS1B, CSNK1A1 PARP1 1797/4885KDM4E 877/4885TNKS 261/4885
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885KDM4E 736/4885TNKS 281/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 PARP1 3/4885KDM4E 1151/4885TNKS 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.